RAS and ROS in Rhabdomyosarcoma  by Zhang, Minsi et al.
Cancer Cell
Previewsincluding endothelial cells and tumor
cells, it will be pivotal to analyze whether
the mechanism proposed by this study
is still evident when Nrp1 activity is
broadly abrogated in murine tumor
models and human tumors. Whether
TAM location and activity is similarly regu-
lated in other hypoxia-generating pathol-
ogies also warrants further investigation.
For example, in a mouse model of cere-
bral stroke, microglia and macrophages
were found to undergo M2 polarization
immediately after ischemic insult, but
eventually underwent M1 polarization
induced by ischemic neurons (Huang
and Feng, 2013). The M2 polarized cells
were found to have a protective effect
on neurons, whereas M1 polarized cells
promoted neuronal destruction; there-
fore, preventing microglia and macro-phages from associating with ischemic
areas might maintain their neuronal-pro-
tective phenotypes. If validated, manipu-
lation of the Nrp1/Sema3A axis could
become a valuable agent for diseases
like ischemia and stroke to redirect
macrophage function and improve patient
outcome.REFERENCES
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The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with
metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA
sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential
therapeutic targets for high-risk embryonal rhabdomyosarcoma.Rhabdomyosarcoma (RMS) is the most
commonly diagnosed soft tissue sarcoma
in children. The two major subtypes, alve-
olar (ARMS) and embryonal (ERMS), differ
in their histological features, genetic
mutations, age of onset, and prognosis
(Parham and Ellison, 2006). ERMS, more
commonly diagnosed in children less
than 10 years of age, is characterized
by the presence of rhabdomyoblasts,
cells with eccentric nuclei and eosino-
philic cytoplasm, embedded in a myxoid
stroma. ARMS, more commonly diag-
nosed in children over 10 years of age, is
distinguished histologically by clusters of
small, round, blue cells in a highly cellularbackground. Most tumors with ARMS
histology have chromosomal transloca-
tions t(2;13)(q35;q14) or t(1;13)(p36;q14),
resulting in the expression of either
PAX3-FOXO1 or PAX7-FOXO1 fusion
proteins, with few other chromosomal
alterations. In contrast, ERMS frequently
possesses multiple chromosomal alter-
ations. Although most cases of RMS
occur sporadically, inherited syndromes
with germline mutations associated with
developing RMS include Neurofibroma-
tosis Type I (NF1) (Ferrari et al., 2007), Li-
Fraumeni (TP53) (Diller et al., 1995), Cost-
ello (HRAS) (Kratz et al., 2011), Noonan
(PTPN11, SOS1, RAF1, KRAS, NRAS,and BRAF) (Kratz et al., 2011), and Gorlin
syndromes (PTCH1) (Gorlin, 1987).
The current clinical criteria for classifi-
cation of RMS into low-, intermediate-,
or high-risk groups depend on primary
tumor site, size, surgical resectability,
and metastasis to regional lymph nodes
or distant sites (Malempati and Hawkins,
2012). Whereas the high-risk group en-
compasses metastatic RMS of both alve-
olar and embryonal subtypes regardless
of primary tumor size or site, ARMS
patients generally have worse clinical
outcomes than ERMS patients. Impor-
tantly, ARMS that is diagnosed at the his-
tological level and lacking PAX3-FOXO1December 9, 2013 ª2013 Elsevier Inc. 689
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Previewsor PAX7-FOXO1 translocation is more
similar to ERMS in both gene expression
and clinical outcome (Williamson et al.,
2010). Treatment for RMS is multimodal
and includes chemotherapy, radiation
therapy, and surgery. Although patients
with localized RMSwho receive combina-
tion therapy have a 5-year survival greater
than 70%, relapse and poor outcome are
common for patients with metastasis at
the time of diagnosis. Thus, it is important
to gain a better understanding of these
aggressive tumors at the molecular level
and insight into how they are biologically
different from those with better clinical
outcomes. This information may inform
risk stratification for current therapies
and the development of novel treatments.
In this issue of Cancer Cell, Chen et al.
(2013) performed genomic and RNA
sequencing of human ERMS and ARMS
to identify novel differentiating character-
istics for high-risk ERMS.
Using data from29ERMSand 17ARMS
specimens, Dyer andcolleagues identified
recurrent genetic lesions, including single
nucleotide variations, indels, and struc-
tural variants, in eight consensus cancer
genes for ERMS (NRAS, KRAS, TP53,
NF1, RARA, CTNNB2, CARD11, and
PIK3CA) and two translocations for
ARMS (PAX3-FOXO1 and PAX7-FOXO1)
(Chen et al., 2013). They identified no mu-
tations in the SHH pathway. TP53 gene
mutations were associated with concur-
rent FGFR4 mutations, and mutations in
the p53 pathway were overall more
frequent in ERMS than in ARMS. The
RAS pathway—specifically RAS family
members NRAS, KRAS, and HRAS and
the RAS-GAP NF1—were identified as
the most commonly mutated genes in
ERMS. The authors failed to find an asso-
ciation of RAS pathway mutations with
mutations in the p53, RB, or SHH path-
ways as previously suggested (Rubin
et al., 2011), but epigenetic modifications
maybecontributing to thesepreviously re-
ported associations at the transcriptome
level. Importantly, RAS pathway mutation
status was significantly associated with
ERMS risk group classification, withmuta-
tions found in 75% of high-risk ERMS,
45% of intermediate-risk ERMS, and 0%
of low-risk ERMS. Moreover, none of the
ARMS samples had RAS pathway muta-
tions. These findings are consistent with
prior studies that identified RAS pathway
mutations in ERMS (Paulson et al., 2011).690 Cancer Cell 24, December 9, 2013 ª201If this correlation with ERMS risk groups
is validated in a larger data set, genotyping
for RAS pathway mutations could poten-
tially be used to improve ERMS risk
stratification.
In this study, all current RAS pathway
inhibitors tested, including 13 MEK/ERK
inhibitors and 17 PI3K inhibitors, failed
to show significant activity on patient-
derived NRAS mutant xenografts. The
only exception was BGT-226. Treatment
with this dual PI3K/mTOR inhibitor led to
tumor responses in the 100–1,000 nM
range. The efficacy of this agent may be
due in part to inhibition of other PI3K-
related kinases, such as ATM and/or
DNA-PKcs. Therefore, novel small mole-
cules that directly inhibit mutant RAS itself
may be needed to treat patients with
aggressive ERMS with a confirmed RAS
mutation.
Chen et al. (2013) also detected more
G/T transversions in RMS than in both
T-ALL and medulloblastoma combined.
Thus, although RMS is a childhood
cancer, it is subjected to more oxidative
damage-induced mutations than other
childhood tumor types. Interestingly, the
rate of G/T transversions was more
common in ERMS than ARMS, but not as
common as in lung cancer. The increase
in G/T transversions in ERMS correlated
with increased p38 MAPK activity as
measured by upregulation of MAPK12
and MAP2K6. Prior studies reported
that RAS pathway mutations, which are
frequently observed in adult cancers of
the lung, colon, and pancreas, increase
oxidative stress in tumors to fuel RAS-
driven oncogenesis (Weinberg et al.,
2010). Together, these data suggest that
ERMS, especially those classified as inter-
mediate- or high-risk ERMS, may behave
more biologically like adult cancers, which
are more commonly associated with
oxidative damage. These findings should
prompt biochemical analyses to quantify
the extent of oxidative stress in ERMS in
different risk groups as compared to
ARMS and other cancers. Interestingly,
patient-derived ERMS xenografts re-
sponded to drugs that modify oxidative
stress. If validated, regulators of oxidative
stress and ROS production may provide
new therapeutic options for intermediate-
and high-risk ERMS.
To gain insight into the temporal
dynamics of gene mutation in RMS, the
authors obtained three recurrent RMS3 Elsevier Inc.from two separate ERMS patients. The
sequencing analyses comparing the diag-
nostic sample with the recurrent tumor(s)
led to a number of clinically relevant find-
ings. Gene clusters showed that all tu-
mors contained more than one clone,
and in each of the two diagnostic tumors,
the major clone was eliminated after
combination therapy. The minor clone in
each tumor accumulated further muta-
tions, generating two subclones within
the recurrent tumor of one patient and
six subclones between the two recurrent
tumors of the other patient. Therefore,
repeated biopsy at each instance of
recurrent or metastatic disease may iden-
tify new molecular targets to guide ther-
apy. Moreover, these results may explain
why patients with multiple metastatic
ERMS lesions show a mixed response to
systemic therapy.
In summary, Chen et al. (2013)
performed whole-genome and RNA
sequencing on human ARMS and ERMS
samples and identified frequent p53
and RAS pathway mutations in ERMS.
These mutations may inform ERMS risk
stratification and provide important, but
potentially challenging, targets for future
drug development. The authors also
found the oxidative stress pathway was
upregulated in ERMS, and correspond-
ingly, drugs that modify oxidative stress
showed activity in patient-derived ERMS
xenograft models, suggesting that further
investigation of this drug class is war-
ranted. Finally, because the authors noted
dramatic differences in the genetic land-
scape between primary diagnostic sam-
ples and recurrent tumors, clinical trials
testing molecularly targeted agents in pa-
tients with progressive disease should be
based on biopsies of metastatic lesions
rather than original diagnostic biopsies.
Combined, these findings provide a better
understanding of the genetic landscape
of RMS and suggest that future advances
in the treatment of ERMS will be through
RAS and ROS.
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An elegant paper by Anchoori and colleagues in this issue ofCancer Cell describes an irreversible inhibitor of
Rpn13, one of the ubiquitin receptors on the 26S proteasome that is nonessential for proteasome function in
most normal tissues, but is overexpressed in many solid tumors.The proteasome is an essential compo-
nent of the protein quality control appa-
ratus in every eukaryotic cell. The load on
the proteasomes in cancer cells is higher
than in their nonmalignant counterparts,
causing them to be more sensitive to pro-
teasome inhibitors (Cenci et al., 2011).
Since the introduction of bortezomib
(Velcade) for the treatment of multiple
myeloma 10 years ago, proteasome inhib-
itors have attracted major interest from
drug companies and academic labora-
tories. Most companies have focused
their efforts on designing inhibitors of the
chymotrypsin-like sites of the 20S proteo-
lytic core, which play the major role in
protein breakdown and are the primary
targets of bortezomib. Last year, the
Food and Drug Administration (FDA)
approved a second proteasome inhibitor,
carfilzomib (Kyprolis), for the treatment of
relapsedand refractorymultiplemyeloma.
Four additional inhibitors are currently un-
dergoing clinical trials (Molineaux, 2012).
The 26S proteasome is an unusual
target, because it presents multiple op-
portunities for therapeutic intervention. In
addition to three pairs of distinct activesites within its proteolytic core, it contains
multiple targets within its 19S regulatory
complexes (Figure 1). The function of the
regulatory complex is to recognize pro-
teins marked for degradation by the
attachment of ubiquitin chains, unfold
these proteins, and recycle ubiquitin.
Each 19S complex contains six ATPases,
three de-ubiquitylating enzymes, and at
least two ubiquitin receptors, all of which
are potential targets for therapeutic inter-
vention. The elegant study in this issue of
Cancer Cell by Anchoori et al. (2013) de-
scribes the first inhibitor of one of the ubiq-
uitin receptors, Rpn13.
Following up on their earlier study,
which identified an amino acid substituted
1,3-diphenyl-1-one (chalcone) as an in-
hibitor of the ubiquitin-proteasome sys-
tem that killed cervical cancer cells
(Anchoori et al., 2011), Roden and his col-
laborators set out to improve the potency
and bioavailability of their compound.
This effort led to the discovery of RA190,
which induced apoptosis in bortezomib-
resistant myeloma cells and several cervi-
cal and ovarian cancer cell lines. Although
it induced an accumulation of ubiquity-lated proteins and stabilized luciferase
reporter substrates, hallmarks of protea-
some inhibition, it failed to inhibit any of
the three active sites of the 20S proteo-
lytic core. A combination of chemical
modification and washout experiments
convinced the authors that RA190 is an
irreversible inhibitor, allowing them to
convert it into an activity-based probe.
This probe labeled just one polypeptide
in the cell, which, through a series of
elegant biochemical experiments, was
identified as Rpn13. Further analysis by
site-directed mutagenesis and nuclear
magnetic resonance (NMR) revealed that
Cys-88 in the Rpn13 ubiquitin-binding
domain is modified by the drug. Surpris-
ingly, Cys-88 is located on the side of
the domain opposite to the ubiquitin-
binding site, in the region that forms the
interface with another Rpn13 domain,
the Uch37 binding domain (Figure 1A).
Based on analysis of available NMR
data, the authors concluded that RA190
abrogates interactions between the two
Rpn13 domains. Further mechanistic
studies are needed to understand how
this conformational change disruptsDecember 9, 2013 ª2013 Elsevier Inc. 691
